Can Maternal Autoantibodies Play an Etiological Role in ASD Development?
CRMP2
animal models
autism spectrum disorder
maternal autoantibodies
therapy
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
11
2019
accepted:
10
04
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors - both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.
Identifiants
pubmed: 32581542
doi: 10.2147/NDT.S239504
pii: 239504
pmc: PMC7276202
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1391-1398Informations de copyright
© 2020 Dudova et al.
Déclaration de conflit d'intérêts
Dr Iva Dudova, Dr Klara Horackova, Prof. Dr. Michal Hrdlicka and Dr Martin Balastik report grants, personal fees from the Ministry of Health, Czech Republic, during the conduct of the study. The authors report no other conflicts of interest in this work.
Références
Transl Psychiatry. 2018 Aug 10;8(1):148
pubmed: 30097568
Front Psychiatry. 2019 Jun 21;10:440
pubmed: 31293459
Adv Exp Med Biol. 2007;600:1-11
pubmed: 17607942
Transl Psychiatry. 2013 Jul 09;3:e278
pubmed: 23838889
Curr Neuropharmacol. 2019;17(1):33-58
pubmed: 30221603
Lancet. 2018 Aug 11;392(10146):508-520
pubmed: 30078460
CNS Drugs. 2015 Sep;29(9):715-24
pubmed: 26369920
Neurosci Bull. 2017 Apr;33(2):183-193
pubmed: 28213805
J Neurosci. 2010 Mar 24;30(12):4419-27
pubmed: 20335478
Behav Brain Res. 2014 Jun 1;266:46-51
pubmed: 24613242
Cell Rep. 2015 Oct 27;13(4):812-828
pubmed: 26489457
J Child Psychol Psychiatry. 2016 May;57(5):585-95
pubmed: 26709141
Dialogues Clin Neurosci. 2017 Dec;19(4):353-371
pubmed: 29398931
Neurosci Bull. 2018 Dec;34(6):1119-1126
pubmed: 29936584
J Autism Dev Disord. 2012 Jul;42(7):1435-45
pubmed: 22012245
Neuropsychopharmacology. 2017 Jan;42(1):284-298
pubmed: 27534269
Brain Behav Immun. 2013 May;30:61-5
pubmed: 23395715
Brain Behav Immun. 2008 Aug;22(6):806-16
pubmed: 18262386
Dev Med Child Neurol. 1980 Dec;22(6):719-24
pubmed: 7450298
Neurosci Biobehav Rev. 2015 Aug;55:322-32
pubmed: 25981892
Arch Gen Psychiatry. 2005 Dec;62(12):1366-76
pubmed: 16330725
Nat Biotechnol. 2005 Oct;23(10):1283-8
pubmed: 16186811
J Neuroimmunol. 2012 Nov 15;252(1-2):56-65
pubmed: 22951357
J Biol Chem. 2011 Dec 2;286(48):41466-78
pubmed: 21953449
EMBO Rep. 2020 Mar 4;21(3):e48512
pubmed: 31919978
Cell. 2005 Jan 14;120(1):137-49
pubmed: 15652488
Autism Res. 2018 May;11(5):707-712
pubmed: 29394471
Cereb Cortex. 2016 Jan;26(1):374-383
pubmed: 25535268
Epidemiology. 2010 Nov;21(6):805-8
pubmed: 20798635
Eur J Neurosci. 2003 Jun;17(11):2329-43
pubmed: 12814366
Brain Res. 1975 Jul 18;92(3):405-13
pubmed: 1174960
Mol Psychiatry. 2016 Dec;21(12):1663-1671
pubmed: 27698429
J Neuroimmunol. 2009 Jun 25;211(1-2):39-48
pubmed: 19362378
J Neurosci. 1996 Oct 1;16(19):6197-207
pubmed: 8815901
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20195-200
pubmed: 22123952
Transl Psychiatry. 2013 Jul 09;3:e277
pubmed: 23838888
Dev Dyn. 2018 Apr;247(4):588-619
pubmed: 29226543
Biol Psychiatry. 2008 Oct 1;64(7):583-8
pubmed: 18571628
Nat Commun. 2016 Jun 01;7:
pubmed: 27249678
Neurology. 2001 Jul 24;57(2):245-54
pubmed: 11468308
Biol Psychiatry. 2017 Mar 1;81(5):383-390
pubmed: 28340985
Trends Neurosci. 2008 Mar;31(3):137-45
pubmed: 18258309
Neuroscientist. 2014 Dec;20(6):589-98
pubmed: 24402611
Anaesth Intensive Care. 2010 Mar;38(2):387-9
pubmed: 20369779
Mol Psychiatry. 2018 Jun 28;:
pubmed: 29955164
J Autoimmun. 2016 Feb;67:1-7
pubmed: 26725748
Neurotoxicology. 2008 Mar;29(2):226-31
pubmed: 18078998
Mol Psychiatry. 2019 Feb;24(2):252-265
pubmed: 29934547
Biomarkers. 2018 Nov;23(7):622-624
pubmed: 29578363
J Autism Dev Disord. 2010 Dec;40(12):1423-30
pubmed: 20414802